• Platelets
• stroke
• arrhythmias
• atherosclerosis

To the Editor We read with interest the meta-analysis by Siller-Matula et al, which reported that intensified clopidogrel loading with 600 mg reduces the rate of major cardiovascular events without increase in major bleeding compared with 300 mg in patients undergoing percutaneous coronary intervention (PCI) during 1-month follow-up.1 A large body of evidence has suggested the effectiveness and safety of the 600 mg loading dose of clopidogrel for patients with acute coronary syndrome undergoing primary PCI. Besides, many experts indicated that the benefits of additional antiplatelet agents were mainly for those with high-risk profiles and advanced Killip's classifications.2 Accordingly, the authors raised a critical concern …